- Home
- BP vs REGN Comparison
BP vs REGN Comparison
Compare BP & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BP | REGN |
|---|---|---|
| Founded | 1889 | 1988 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 96.5B | 79.4B |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | BP | REGN |
|---|---|---|
| Price | $40.41 | $759.58 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 23 |
| Target Price | $40.56 | ★ $815.04 |
| AVG Volume (30 Days) | ★ 9.0M | 638.2K |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | ★ 4.98% | 0.49% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | N/A | ★ 41.48 |
| Revenue | N/A | ★ $5,872,227,000.00 |
| Revenue This Year | $0.19 | $11.69 |
| Revenue Next Year | $0.79 | $10.12 |
| P/E Ratio | $11,332.35 | ★ $18.41 |
| Revenue Growth | N/A | ★ 20.82 |
| 52 Week Low | $25.22 | $476.49 |
| 52 Week High | $39.56 | $821.11 |
Technical Indicators
Market Signals| Indicator | BP | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 64.11 | 45.70 |
| Support Level | $33.43 | $740.39 |
| Resistance Level | N/A | $786.67 |
| Average True Range (ATR) | 0.72 | 21.54 |
| MACD | 0.07 | -2.98 |
| Stochastic Oscillator | 93.62 | 18.91 |
Price Performance
Historical ComparisonAbout BP BP p.l.c.
BP is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2024, it produced 1.2 million barrels of liquids and 6.9 billion cubic feet of natural gas per day. At the end of 2024, reserves stood at 6.2 billion barrels of oil equivalent, 59% of which are liquids. The company operates refineries with a capacity of 1.6 million barrels of oil per day.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).